Shanton Pharma's SAP-001 Shows Promising Results in Gout Study
Shanton Pharma's Breakthrough in Gout Treatment
SAP-001, Shanton's leading investigational compound, is setting the stage for advancements in gout treatment. The company recently released encouraging topline data from a Phase 2b study focused on patients suffering from refractory gout. This study highlights the effectiveness of SAP-001, which employs a First-in-Class Mechanism of Action targeted at a specific kidney transporter.
Positive Outcomes from the Phase 2b Study
In a recent announcement, Shanton Pharma shared results from their Phase 2b clinical study involving patients with refractory gout. According to Dr. Bing Li, the CEO of Shanton, the results were nothing short of promising. He noted that by month three of the study, almost all participants receiving SAP-001 at daily doses of 30 and 60 mg alongside standard treatments achieved serum uric acid levels below 6 mg/dL. This is a significant improvement compared to the mere 10% of patients on standard therapy who reached this target.
Lasting Effects and Safety Profile
Notably, the beneficial effects of SAP-001 continued throughout the treatment period, with more than half of the patients in the 60 mg group achieving serum uric acid levels under 3 mg/dL. Dr. Li emphasized the drug's excellent safety profile, which is essential for patients who often have limited treatment options due to the nature of their conditions.
Understanding Gout and Its Challenges
Gout is recognized as the most prevalent form of inflammatory arthritis, impacting millions globally. It arises from excessive uric acid in the blood, leading to painful joint inflammation. With over 12 million diagnosed patients in the U.S. alone, chronic gout can result in significant joint deterioration if left untreated. Alarmingly, around 29% of these patients are on urate-lowering therapies, yet only about half achieve satisfactory results. This statistic indicates a substantial need for more effective treatments tailored for refractory patients.
Details of Shanton's Clinical Study
The Phase 2b study conducted by Shanton Pharma was a rigorous six-month, randomized, double-blind, placebo-controlled trial addressing refractory gout patients with or without tophi. Over 87 patients were enrolled from multiple sites across the U.S., aiming to evaluate the efficacy and safety of SAP-001 in varying doses of 10, 30, and 60 mg.
Primary and Secondary Study Objectives
Shanton's primary goal was to measure how effectively SAP-001 decreased serum urate levels in patients who were unresponsive to standard treatment based on Xanthine Oxidase Inhibitor therapy. Secondary objectives also included tolerability assessments and reporting the frequency of gout flares, essential factors in overall patient well-being.
The Future of Gout Treatment
Shanton Pharma, founded in 2016 and headquartered in Singapore, is dedicated to addressing unmet medical needs in hyperuricemia and gout. With the innovative approach of SAP-001, the company aims to introduce a once-daily oral therapy that demonstrates exceptional efficacy in patients who are often resistant to existing treatments. The unique mechanism of SAP-001 offers a new avenue to mitigate symptoms and improve lives.
Frequently Asked Questions
What is SAP-001?
SAP-001 is Shanton Pharma's investigational drug designed to treat gout, specifically targeting a distinct kidney transporter for urate lowering.
What were the results of the Phase 2b study?
The Phase 2b study showed that nearly all patients treated with SAP-001 reached serum uric acid levels below 6 mg/dL, demonstrating its efficacy.
What is the significance of the study's findings?
The findings suggest that SAP-001 could be a breakthrough treatment for refractory gout patients who struggle with conventional therapies.
How does gout develop?
Gout develops from high levels of uric acid in the blood, leading to the formation of urate crystals in joints, causing painful inflammation.
What is the next step for Shanton Pharma?
Shanton Pharma aims to advance SAP-001 into pivotal studies, seeking to offer a transformative treatment option for gout patients in the near future.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
